Lucentis is a prescription medication given by injection into the eye. Lucentis has been associated with detached retina and serious eye infection and should not be used in patients who have an ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved ...

<0> GenentechMedia Contact:Terence Hurley, 650-467-6800orInvestor Relations:Thomas Kudsk Larsen, 650-467-2016Karl Mahler, 011 41 61 687 8503 </0> Genentech, a member of the Roche Group (SIX: RO, ROG; ...

The Lucentis 0.3 mg PFS, which is made of borosilicate glass and is packaged in a single-use sterile, sealed tray, allows physicians to eliminate several steps in the preparation and administration ...

Please refer to the SmPC before prescribing Lucentis 10 mg/ml solution vial for injection, or Lucentis 10 mg/ml solution for injection in pre-filled syringe Presentations: A glass single-use vial ...

The cancer drug Avastin may work just as effectively as the more expensive Lucentis at treating age-related macular degeneration, new research suggests. But the potential side effects bear watching.

Two patients receiving intravitreal ranibizumab (Lucentis) for wet age-related macular degeneration complained immediately after their injection of unusual visual symptoms, ‘like looking through an ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) ...

Avastin, a drug by Genentech approved to treat cancer but commonly used off-label to treat age-related macular degeneration, is as effective as the Food and Drug Administration-approved drug Lucentis ...

REDWOOD CITY, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that the U.S. Food and Drug Administration (FDA) has ...

ZURICH (Reuters) - Switzerland's Novartis and Roche were fined 444 million euros (403.55 million pounds)by France, after its competition authority said on Wednesday they used abusive practices to push ...